Willingness-to-Pay and Benefit–Cost Analysis of Botulinum Toxin for the Treatment of Rosacea in China: Findings from a Web-Based Survey

References

• van Zuuren EJ. Rosacea. N Engl J Med. 2017;377(18):1754–1764. doi:10.1056/NEJMcp1506630
   PubMed Web of Science ®Google Scholar
• Buddenkotte J, Steinhoff M. Recent advances in understanding and managing rosacea. F1000Res. 2018;7. doi:10.12688/f1000research.16537.1
   Google Scholar
• Gether L, Overgaard LK, Egeberg A, Thyssen JP. Incidence and prevalence of rosacea: a systematic review and meta-analysis. Br J Dermatol. 2018;179(2):282–289. doi:10.1111/bjd.16481
   PubMed Web of Science ®Google Scholar
• Li J, Wang B, Deng Y, et al. Epidemiological features of rosacea in Changsha, China: a population-based, cross-sectional study. J Dermatol. 2020;47(5):497–502. doi:10.1111/1346-8138.15301
   PubMed Web of Science ®Google Scholar
• Ahn CS, Huang WW. Rosacea pathogenesis. Dermatol Clin. 2018;36(2):81–86. doi:10.1016/j.det.2017.11.001
   PubMed Web of Science ®Google Scholar
• Zhang H, Tang K, Wang Y, Fang R, Sun Q. Rosacea treatment: review and update. Dermatol Ther (Heidelb). 2021;11(1):13–24. doi:10.1007/s13555-020-00461-0
   PubMed Web of Science ®Google Scholar
• Thiboutot D, Anderson R, Cook-Bolden F, et al. Standard management options for rosacea: the 2019 update by the National Rosacea Society Expert Committee. J Am Acad Dermatol. 2020;82(6):1501–1510. doi:10.1016/j.jaad.2020.01.077
   PubMed Web of Science ®Google Scholar
• Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11):1369–1371. doi:10.1001/archderm.143.11.1369
   PubMedGoogle Scholar
• Fowler J, Jackson M, Moore A, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650–656.
   PubMed Web of Science ®Google Scholar
• França K, Kumar A, Fioranelli M, Lotti T, Tirant M, Roccia MG. The history of Botulinum toxin: from poison to beauty. Wien Med Wochenschr. 2017;167(Suppl 1):46–48. doi:10.1007/s10354-017-0553-7
   Google Scholar
• Scala J, Vojvodic A, Vojvodic P, et al. Botulin toxin use in rosacea and facial flushing treatment. Open Access Maced J Med Sci. 2019;7(18):2985–2987. doi:10.3889/oamjms.2019.784
   PubMedGoogle Scholar
• Choi JE, Werbel T, Wang Z, Wu CC, Yaksh TL, Di Nardo A. Botulinum toxin blocks mast cells and prevents rosacea like inflammation. J Dermatol Sci. 2019;93(1):58–64. doi:10.1016/j.jdermsci.2018.12.004
   Web of Science ®Google Scholar
• Friedman O, Koren A, Niv R, Mehrabi JN, Artzi O. The toxic edge – a novel treatment for refractory erythema and flushing of rosacea. Lasers Surg Med. 2019;51(4):325–331. doi:10.1002/lsm.23023
   Web of Science ®Google Scholar
• Kim MJ, Kim JH, Cheon HI, et al. Assessment of skin physiology change and safety after intradermal injections with botulinum toxin: a randomized, double-blind, placebo-controlled, split-face pilot study in rosacea patients with facial erythema. Dermatol Surg. 2019;45(9):1155–1162. doi:10.1097/dss.0000000000001819
   Web of Science ®Google Scholar
• Al-Niaimi F, Glagoleva E, Araviiskaia E. Pulsed dye laser followed by intradermal botulinum toxin type – a in the treatment of rosacea-associated erythema and flushing. Dermatol Ther. 2020;33(6):e13976. doi:10.1111/dth.13976
   Web of Science ®Google Scholar
• Xiao Y, Chen L, Jing D, et al. Willingness-to-pay and benefit-cost analysis of chemical peels for acne treatment in China. Patient Prefer Adherence. 2019;13:363–370. doi:10.2147/ppa.S194615
   Web of Science ®Google Scholar
• Thomas K, Yelverton CB, Yentzer BA, Balkrishnan R, Fleischer AB, Feldman SR. The cost-effectiveness of rosacea treatments. J Dermatolog Treat. 2009;20(2):72–75. doi:10.1080/09546630802314662
   PubMed Web of Science ®Google Scholar
• Taieb A, Stein Gold L, Feldman SR, Dansk V, Bertranou E. Cost-effectiveness of ivermectin 1% cream in adults with papulopustular rosacea in the United States. J Manag Care Spec Pharm. 2016;22(6):654–665. doi:10.18553/jmcp.2016.15210
   PubMed Web of Science ®Google Scholar
• Mitchell RC, Carson RT. Using Surveys to Value Public Goods: The Contingent Valuation Method. Washington, DC: Resources for the Future; 2013.
   Google Scholar
• China. N.B.o.S.o.t.P.s.R.o. China Labour Statistical Yearbook 2019. Beijing: China Statistics Press; 2019.
   Google Scholar
• China. N.H.C.o.t.P.s.R.o. 2019 Yearbook of Health Statistics of China. Beijing: Beijing Union Medical University Press; 2019.
   Google Scholar
• Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x
   PubMed Web of Science ®Google Scholar
• Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159(5):997–1035. doi:10.1111/j.1365-2133.2008.08832.x
   PubMed Web of Science ®Google Scholar
• Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Investig Dermatol Symp Proc. 2004;9(2):169–180. doi:10.1111/j.1087-0024.2004.09113.x
   PubMed Web of Science ®Google Scholar
• Wu Y, Fu C, Zhang W, Li C, Zhang J. The Dermatology Life Quality Index (DLQI) and the hospital anxiety and depression (HADS) in Chinese rosacea patients. Psychol Health Med. 2018;23(4):369–374. doi:10.1080/13548506.2017.1361540
   PubMed Web of Science ®Google Scholar
• VanBeek MJ. Integrating patient preferences with health utilities: a variation on health-related quality of life. Arch Dermatol. 2008;144(8):1037–1041. doi:10.1001/archderm.144.8.1037
   Google Scholar
• Beikert FC, Langenbruch AK, Radtke MA, Augustin M. Willingness to pay and quality of life in patients with rosacea. J Eur Acad Dermatol Venereol. 2013;27(6):734–738. doi:10.1111/j.1468-3083.2012.04549.x
   PubMed Web of Science ®Google Scholar
• Tan J, Steinhoff M, Bewley A, Gieler U, Rives V. Characterizing high-burden rosacea subjects: a multivariate risk factor analysis from a global survey. J Dermatolog Treat. 2020;31(2):168–174. doi:10.1080/09546634.2019.1623368
   PubMed Web of Science ®Google Scholar
• Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. Int J Dermatol. 2008;47(3):284–288. doi:10.1111/j.1365-4632.2008.03445.x
   PubMed Web of Science ®Google Scholar
• Williamson T, Cheng WY, McCormick N, Vekeman F. Patient preferences and therapeutic satisfaction with topical agents for rosacea: a survey-based study. Am Health Drug Benefits. 2018;11(2):97–106.
   Web of Science ®Google Scholar
• Zeichner JA, Eichenfield LF, Feldman SR, Kasteler JS, Ferrusi IL. Quality of life in individuals with erythematotelangiectatic and papulopustular rosacea: findings from a web-based survey. J Clin Aesthet Dermatol. 2018;11(2):47–52.
   Google Scholar
• Qi S, Zhixiang Z, Hongfu X, Ji L, Ben W. Analysis of clinical features of intermittent flushing in patients with rosacea and its impact on quality of life. Chine J Dermatol. 2020;53(5):340–344. doi:10.35541/cjd.20191198
   Google Scholar